Stocks News

LAST PRICE
1.1000
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
1.0400/ 17
Ask / Lots
1.1200/ 1
Open / Previous Close
--- / 1.1000
Day Range
---
52 Week Range
Low 0.6800
High 4.1000
Volume
82
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 12, 2024
- -- Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000, from 8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires
  8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: OVID
  08:05 AM EST, 11/12/2024 (MT Newswires) -- ...
- *DJ Ovid Therapeutics 3Q Loss/Shr 20c >OVID, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: OVID
- Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: OVID
  
  Third Quarter 2024 Financial Results
  -- Cash, cash equivalents and marketable securities as of September 30, 2024, totaled $62.7 million. -- Revenues from royalty agreements were $173,000 for the third quarter ended September 30, 2024, as compared to $109,000 in the same period in 2023. -- Research and development expenses were $7.9 million for the third quarter ended September 30, 2024, compared to $5.3 million in the same period in 2023. The increase is related to the advancement of Ovid's clinical and preclinical pipeline programs as described above. -- General and administrative expenses were $5.5 million for the third quarter ended September 30, 2024, as compared to $6.8 million for the same period in 2023. The decrease was driven by the previous organizational restructuring and related cost-reduction efforts. -- Total operating expenses were $13.4 million for the third quarter ended September 30, 2024, as compared to $12.1 million for the same period last year. -- Ovid reported a net loss of $14.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.20, for the third quarter of 2024, as compared to a net loss of $11.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.16, for the same period in 2023.
Oct 31, 2024
- Ovid Therapeutics to Host Investor Event, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: OVID
  
  Ovid Therapeutics to Host Investor Event
  
  KCC2 Download Day on Wednesday, November 13, 2024
  
  NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously.

Nov 18, 2024
- Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma, from 4:00PM ET on Monday Nov 18, 2024 by Dow Jones
  4:00PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ACET
- Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
  7:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ACET
Nov 16, 2024
- Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024, from 9:00AM ET on Saturday Nov 16, 2024 by Dow Jones
  9:00AM ET on Saturday Nov 16, 2024 by Dow Jones
  Companies Mentioned: ACET
Nov 15, 2024
- DJ VolitionRX Is Maintained at Buy by D. Boral Capital, from 5:05PM ET on Friday Nov 15, 2024 by Dow Jones
  5:05PM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: VNRX
Nov 14, 2024
- *DJ VolitionRX 3Q Rev $475,000 >VNRX, from 4:24PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:24PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VNRX
- VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update, from 4:10PM ET on Thursday Nov 14, 2024 by PR Newswire
  4:10PM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: VNRX
- VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update, from 4:10PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:10PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VNRX
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ALXO
- Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ALXO
Nov 13, 2024
- Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: SLS

Ovid Therapeutics Inc
NASDAQ:OVIDUnited States

Search Criteria

Nov 12, 2024

-- Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000, from 8:05AM ET on Tuesday Nov 12, 2024 by MT Newswires

*DJ Ovid Therapeutics 3Q Loss/Shr 20c >OVID, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Oct 31, 2024

Ovid Therapeutics to Host Investor Event, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Peers Headlines

Nov 18, 2024

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma, from 4:00PM ET on Monday Nov 18, 2024 by Dow Jones

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 16, 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024, from 9:00AM ET on Saturday Nov 16, 2024 by Dow Jones

Nov 15, 2024

DJ VolitionRX Is Maintained at Buy by D. Boral Capital, from 5:05PM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

*DJ VolitionRX 3Q Rev $475,000 >VNRX, from 4:24PM ET on Thursday Nov 14, 2024 by Dow Jones

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update, from 4:10PM ET on Thursday Nov 14, 2024 by PR Newswire

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update, from 4:10PM ET on Thursday Nov 14, 2024 by Dow Jones

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:15PM ET on Wednesday Nov 13, 2024 by Dow Jones